Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Opioid-Free Total Shoulder With Suzetrigine

10 november 2026 uppdaterad av: OrthoCarolina Research Institute, Inc.

Opioid-Free Postoperative Analgesia With Suzetrigine Following Total Shoulder Arthroplasty: A Prospective Randomized Controlled Noninferiority Trial

This prospective, randomized, unblinded, controlled noninferiority study may benefit patients by determining whether an opioid-free postoperative analgesic pathway utilizing suzetrigine can provide adequate pain control following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing pathway. If effective, this strategy may reduce or eliminate routine postoperative opioid use and associated adverse effects while maintaining patient satisfaction and adequate pain control. More broadly, this study will provide prospective data regarding the effectiveness and safety of suzetrigine following total shoulder arthroplasty and may help inform future opioid-free postoperative pain management protocols.

Studieöversikt

Status

Har inte rekryterat ännu

Detaljerad beskrivning

Objective 1: To determine whether an opioid-free postoperative analgesic pathway utilizing suzetrigine provides noninferior postoperative pain control at 24 hours following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing postoperative analgesic pathway.

Hypothesis 1: Postoperative pain at 24 hours among patients randomized to the opioid-free suzetrigine pathway will be noninferior to postoperative pain among patients randomized to the standard opioid-containing pathway.

Objective 2: To compare postoperative opioid consumption, requirement for rescue opioid analgesia, time to first rescue opioid, postoperative pain scores, opioid-related adverse effects, and patient satisfaction between treatment groups.

Hypothesis 2: Patients randomized to the opioid-free suzetrigine pathway will have lower cumulative postoperative opioid consumption and reduced need for rescue opioid analgesia without clinically meaningful worsening of postoperative pain, or patient satisfaction.

Objective 3: To evaluate the safety profile of suzetrigine following total shoulder arthroplasty by characterizing adverse events, medication-related adverse effects, drug-drug interactions, treatment discontinuation, emergency department visits, unplanned readmissions, and reoperations.

Hypothesis 3: Patients randomized to the opioid-free suzetrigine pathway will have lower rates of opioid-related adverse events, including sedation, respiratory depression, nausea, and constipation, compared with patients randomized to the standard opioid-containing pathway.

Objective 4: To evaluate shoulder-specific functional outcomes and determine whether preoperative patient resilience is associated with postoperative pain control, opioid requirements, rescue opioid use, and patient satisfaction.

Hypothesis 4: Shoulder-specific patient-reported outcomes will be comparable between treatment groups. Greater preoperative resilience, as measured by the CD-RISC-10, will be associated with lower postoperative pain, reduced opioid consumption, decreased need for rescue opioid analgesia, and greater satisfaction with pain control.

Studietyp

Interventionell

Inskrivning (Beräknad)

52

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Age ≥18 years
  2. Undergoing elective primary anatomic or reverse total shoulder arthroplasty
  3. English-speaking (for patient-reported outcome assessments)

Exclusion Criteria:

  1. Revision arthroplasty procedures

  2. Total shoulder arthroplasty performed for a fracture-related indication, including acute fractures and chronic fracture sequelae (e.g., malunion or nonunion)

  3. History of chronic opioid use (defined as daily or near-daily use for ≥90 days preoperatively)

  4. Contraindications to suzetrigine:

    1. Known allergy or hypersensitivity to suzetrigine
    2. Current use of strong CYP3A inhibitors (contraindicated per FDA labeling)
    3. Current use of strong or moderate CYP3A inducers (should be avoided per FDA labeling)
    4. Severe hepatic impairment (Child-Pugh Class C)
    5. Severe renal impairment (eGFR <15 mL/min/1.73 m²)
  5. Pregnancy or breastfeeding

  6. Inability to complete patient-reported outcome measures

  7. Simultaneous bilateral arthroplasty

  8. Unable or unwilling to provide informed consent or comply with study procedures

  9. Total shoulder arthroplasty performed for an oncologic indication

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Standard Opioid-Containing Pathway

Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups.

Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days.

Experimentell: Opioid-Free Suzetrigine Pathway

Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days.

Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pain Numeric Rating Scale (NRS)
Tidsram: 24 hours post-surgery

The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) at 24 hours following surgery.

24 hours post-surgery

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pain Numeric Rating Scale (NRS)
Tidsram: From enrollment to the end of treatment at 1 year

The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain)

From enrollment to the end of treatment at 1 year
Morphine Milligram Equivalents (MME)
Tidsram: 24 hours postoperative

Cumulative opioid consumption converted to MME

24 hours postoperative
Morphine Milligram Equivalents (MME)
Tidsram: 48 hours postoperative

Cumulative opioid consumption converted to MME

48 hours postoperative
Rescue opioid analgesia
Tidsram: From enrollment to the end of treatment at 1 year

Requirement for rescue opioid analgesia (yes/no)

From enrollment to the end of treatment at 1 year
Patient satisfaction with overall pain control
Tidsram: From enrollment to the end of treatment at 1 year

Patient satisfaction with overall pain control, measured on a scale of 0-10 with 0 being less satisfied and 10 being completely satisfied.

From enrollment to the end of treatment at 1 year
Hospital length of stay
Tidsram: At the time of surgery treatment.

Time spent in hospital

At the time of surgery treatment.
American Shoulder and Elbow Surgeons (ASES) Shoulder Score
Tidsram: From enrollment to the end of treatment at 1 year

The American Shoulder and Elbow Surgeons Shoulder Score (ASES) was designed to assess the condition of the shoulder, regardless of disease pathology.

The ASES is a composite instrument, requiring both a physician assessment and a patient-completed portion; however, it is commonly presented as solely the patient-reported survey. This includes a section on pain (7 items) and a section on activities of daily living (10 items). Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition.

From enrollment to the end of treatment at 1 year
Single Assessment Numeric Evaluation (SANE)
Tidsram: From enrollment to the end of treatment at 1 year

Patients are asked: "How would you rate your shoulder today as a percentage of normal (0% to 100% scale, with 100% being a completely normal shoulder)?"

From enrollment to the end of treatment at 1 year
Simple Shoulder Test (SST)
Tidsram: From enrollment to the end of treatment at 1 year

Self-reported questionnaire that evaluates shoulder function, comfort, and strength through simple "yes" or "no" questions that result in 0% (worst function) to 100% (best function) score.

From enrollment to the end of treatment at 1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Nady Hamid, MD, OrthoCarolina Research Institute, Inc.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 december 2026

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera